Immutep Announces European Patent Grant for LAG525 Antibody
November 8th 2019
Immutep Presents Positive Interim Data from Phase II TACTI-002 Trial at SITC
November 1st 2019
IMMUTEP AGM 2019 - Chairman's Address
November 1st 2019
IMMUTEP AGM 2019 - CEO Marc Voigt's CEO Presentation
November 1st 2019
Update - Consolidation Split - IMM
October 28th 2019
Operational Update
October 15th 2019
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
October 10th 2019
Immutep Announces Data Presentations at Upcoming Industry Conferences
October 10th 2019
Immutep Receives A$2.5 Million R&D Tax Incentive from French Government
September 26th 2019
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
September 23rd 2019
Immutep to Receive £4M Milestone Payment from GSK
September 17th 2019
Immutep Announces Japanese Patent Grant for LAG525 Antibody
August 22nd 2019
Immutep Granted European Patent for Eftilagimod Alpha in Cancer
August 6th 2019
Immutep Completes A$6M Entitlement Offer
July 29th 2019
Operational Update
June 25th 2019
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
June 21st 2019
Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy
June 13th 2019
Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial
June 6th 2019
INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”
June 3rd 2019
Immutep Presentation at ASCO 2019
May 23rd 2019
Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy
May 17th 2019
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
May 10th 2019
Immutep Announces Upcoming Industry Conference Participation
April 30th 2019
Operational Update
March 28th 2019
Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
March 26th 2019
Presentation related to webcast 25. March 2019 - Immutep to Present IMP761 Preclinical Results
March 22nd 2019
Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
March 19th 2019
Immutep to Present IMP761 Preclinical Results in Global Webcast
March 8th 2019
Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation
March 7th 2019
Immutep receives A$872,351 R&D Tax Incentive
March 6th 2019
Immutep doses First Patient in TACTI-002 Phase II Trial
March 6th 2019
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
March 5th 2019
Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference
February 26th 2019
Immutep to Present at Upcoming Industry Conferences
January 7th 2019
Immutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic
We use cookies and other tracking technologies to improve your browsing experience on our website, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website, you consent to our use of cookies and other tracking technologies. To learn more about cookies view ourPrivacy policy
